|1.||Rigas, Basil: 19 articles (05/2015 - 12/2002)|
|2.||Huang, Liqun: 13 articles (05/2015 - 10/2010)|
|3.||Gerner, Eugene W: 12 articles (01/2015 - 01/2006)|
|4.||Xie, Gang: 10 articles (05/2015 - 10/2010)|
|5.||Kopelovich, Levy: 8 articles (02/2015 - 03/2003)|
|6.||Giardiello, Francis M: 8 articles (10/2005 - 03/2002)|
|7.||Ouyang, Nengtai: 7 articles (05/2015 - 10/2010)|
|8.||Weissbach, Herbert: 7 articles (11/2014 - 12/2003)|
|9.||Mackenzie, Gerardo G: 7 articles (08/2013 - 10/2010)|
|10.||Meyskens, Frank L: 7 articles (10/2010 - 06/2008)|
09/01/1991 - "There was a significantly greater increase in size of the tumors in the control group (56.4 mm for 26 tumors) compared with the rats receiving sulindac (9.3 mm for 14 tumors). "
09/01/2004 - "Combined treatment with sulindac and ursodeoxycholate was more effective than either agent alone for the prevention of tumors throughout the entire intestine. "
01/01/2015 - "In the CT setting, sulindac alone and DFMO/sulindac combination were effective in reducing tumor number, but not tumor burden growth rate. "
08/15/2001 - "In Apc1638(+/-) mice, targeted inactivation of p21 increased intestinal tumor formation in a gene-dose-dependent manner, but inactivation of p21 completely eliminated the ability of sulindac to both inhibit mitotic activity in the duodenal mucosa and to inhibit Apc-initiated tumor formation. "
01/01/2012 - "In this study, we have shown that the combination of sulindac and DCA enhances the selective killing of A549 and SCC25 cancer cells under the conditions used. "
|2.||Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
03/15/2001 - "Sulindac, a nonsteroidal antiinflammatory drug effective against colorectal tumorigenesis in familial adenomatous polyposis syndrome, suppressed the formation of foci. "
01/01/2006 - "The aim of the present study was to elucidate the effect of sulindac on uncolectomized familial adenomatous polyposis (FAP). "
01/01/1990 - "The aim of this study was to assess the effectiveness of sulindac therapy for eradication of micropolyps in 8 patients with familial polyposis coli. "
12/01/2015 - "Sulindac is chemopreventive and has utility in patients with familial adenomatous polyposis; however, side effects preclude its long-term use. "
04/01/2007 - "The NSAID (non-steroidal anti-inflammatory drug) sulindac is a potent inhibitor of intestinal carcinogenesis in the C57BL/6J-Apc(Min)/J mouse model and is used to treat humans with FAP (familial adenomatous polyposis). "
02/20/1996 - "A second study reported that intervention with the NSAID sulindac for 9 months in young patients with FAP resulted in a significant reduction in both polyp number and size in the rectosigmoid colon. "
11/01/2008 - "Sulindac is effective in the reduction and often in the elimination of numerous smaller pouch polyps. "
11/01/2008 - "Future studies are necessary to determine the role of sulindac and other chemotherapeutic agents in preventing the development of these polyps."
08/01/2007 - "Participants in the Phase IIb study served as a vanguard for a randomized, placebo-controlled prospective Phase III trial of the combination of DFMO and sulindac with the primary study endpoint the prevention of colon polyps. "
09/01/1995 - "Despite attempts to reduce polyp mass by regular endoscopic polypectomy, daily transfusions of blood products, and a trial of the non-steroidal anti-inflammatory agent sulindac, his condition gradually deteriorated and he died of septicaemia."
08/01/1995 - "Low-dose rectal sulindac maintenance therapy is highly effective in achieving complete adenoma reversion without relapse in 87 percent of patients after 33 months. "
01/01/2008 - "Follow-up studies showed positive but variable long-term efficacy for colorectal adenomas, but sulindac appears to lack significant benefit in regressing duodenal adenomas or preventing initial occurrence of adenomas in APC mutation carriers. "
08/18/2005 - "Long-term use of sulindac seems to be effective in reducing dysplasia grade and tubulovillous adenoma of retained colorectal adenoma of FAP patients. "
08/01/2011 - "A Phase III trial treating resected adenoma patients with DFMO plus sulindac demonstrated marked reduction of metachronous adenomas, advanced adenomas and multiple adenomas compared to placebo. "
04/04/2002 - "During the course of the study, adenomas developed in 9 of 21 subjects (43 percent) in the sulindac group and 11 of 20 subjects in the placebo group (55 percent) (P=0.54). "
|5.||Colonic Neoplasms (Colon Cancer)
10/01/2010 - "Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice."
07/01/2014 - "Together, our study provides a therapeutic justification of combined inhibition of CXCR2 and sulindac treatment in colon cancer prevention. "
07/01/2011 - "Study results show that P-S/DFMO is an efficacious drug combination for colon cancer prevention and also show the safety of P-S, which may overcome the limiting side effects of conventional sulindac. "
01/01/2011 - "This study demonstrates that the effect of sulindac treatment in a mouse model of colon cancer may be relevant to the human counterpart and highlights the effect of sulindac treatment on metallohydrolases."
01/01/2011 - "To determine whether this effect is relevant to the human condition, HT-29 human colon cancer cells were treated with sulindac and its metabolites, and compared to results obtained from in vivo mouse studies. "
|4.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|5.||Aspirin (Acetylsalicylic Acid)
|9.||Diclofenac (SR 38)
|10.||Tolmetin (Tolmetin Sodium)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)